References 1 Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110 – 21. 2 Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929 – 39. 3 Ronnblom LE et al. Autoimmunity after alphainterferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115:178 – 83. 4 King JK, Hahn BH. Systemic lupus erythematosus: modern strategies for management: a moving target. Best Pract Res Clin Rheumatol 2007; 21:971 – 87. 5 Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 2011; 127:303 – 12; quiz 13 – 14. 6 Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther 2012; 34:1006 – 22. 7 Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus 2013; 22:372 – 80. 8 Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008; 17:271 – 3. 9 Ruiz-Irastorza G et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20 – 8. 10 Levy RA et al. Hydroxychloroquine( HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10:401 – 4. 11 Pons-Estel GJ et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61:830 – 9. 12 Hench PS et al. The effects of the adrenal cortical hormone 17-hydroxy-11- dehydrocorticosterone( Compound E) on the acute phase of rheumatic fever; preliminary report. Proc Staff Meet Mayo Clin 1949; 24:277 – 97. 13 Apostolopoulos D, Morand EF. It hasn’ t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology( Oxford) 2017; 56( suppl _ 1): i114-i122. 14 Bertsias G et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67:195 – 205. 15 Barile-Fabris L et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64:620 – 5. 16 Contreras G et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14 Suppl 1: s33 – 8. 17 Houssiau FA et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121 – 31. 18 Boumpas DT et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741 – 5. 19 Austin HA 3rd et al. Therapy of lupus nephritis. Controlled trial of |
prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614 – 19. 20 Gourley MF et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125:549 – 57. 21 Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther 2012; 14:202. 22 Gunnarsson I et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamideresistant proliferative lupus nephritis. Arthritis Rheum 2007; 56:1263 – 72. 23 Mok CC. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant 2016; 31:1561 – 6. 24 Fei Y et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol 2013; 31:62 – 8. 25 Li X et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012; 27:1467 – 72. 26 Hannah J, Casian A, D’ Cruz D. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. Autoimmun Rev 2016; 15:93 – 101. 27 Alexander T et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015; 74:1474 – 8. 28 Monneaux F et al. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR / lpr mice. Eur J Immunol 2003; 33:287 – 96. 29 Monneaux F et al. Intramolecular T cell spreading in unprimed MRL / lpr mice: importance of the U1-70k protein sequence 131-151. Arthritis Rheum 2004; 50:3232 – 8. 30 Monneaux F et al. Selective modulation of CD4 + T cells from lupus patients by a promiscuous, protective peptide analog. J Immunol 2005; 175:5839 – 47. 31 Monneaux F et al. Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus. Arthritis Res Ther 2007; 9: R111. 32 Page N et al. The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. PLoS One 2009; 4: e5273. 33 Page N et al. HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus. Ann Rheum Dis 2011; 70:837 – 43. 34 Zimmer R et al. Lupuzor / P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013; 72:1830 – 5. 35 Navarra SV et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721 – 31. 36 Furie R et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that |
inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918 – 30. 37 Baker KP et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48:3253 – 65. 38 Terrier B et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62:2458 – 66. 39 Diaz-Lagares C et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11:357 – 64. 40 Boletis JN et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24:2157 – 60. 41 Jonsdottir T et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology( Oxford) 2010; 49:1502 – 4. 42 Jonsdottir T et al. Rituximabtreated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann Rheum Dis 2011; 70:1172 – 3. 43 Li EK et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology( Oxford) 2009; 48:892 – 8. 44 Pepper R et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009; 24:3717 – 23. 45 Sfikakis PP et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52:501 – 13. 46 Vigna-Perez M et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83. 47 Leandro MJ et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46:2673 – 7. 48 Looney RJ et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I / II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580 – 9. 49 Leandro MJ et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology( Oxford) 2005; 44:1542 – 5. 50 Ng KP et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006; 65:942 – 5. 51 Jonsdottir T et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008; 67:330 – 4. 52 Jonsdottir T et al. Long-term follow-up in lupus nephritis patients treated with rituximab – clinical and histopathological response. Rheumatology( Oxford) 2013; 52:847 – 55. 53 van Vollenhoven RF et al. Biopsy-verified response of severe lupus nephritis to treatment with |
rituximab( anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004; 33:423 – 7. 54 Rovin BH et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215 – 26. 55 Merrill JT et al. Efficacy and safety of rituximab in moderatelyto-severely active systemic lupus erythematosus: the randomized, double-blind, phase II / III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222 – 33. 56 Bertsias GK et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association( EULAR / ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771 – 82. 57 Hahn BH et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res( Hoboken) 2012; 64:797 – 808. 58 Ramos-Casals M et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010; 28:468 – 76. 59 Witt M et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus( SLE) – results from a nationwide cohort in Germany( GRAID). Lupus 2013; 22:1142 – 9. 60 Ryden-Aulin M et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci Med 2016; 3: e000163. 61 van Vollenhoven RF et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebocontrolled trial. Arthritis Rheum 2011; 63:1782 – 92. 62 Ginzler EM et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012; 14: R33. 63 Furie RA et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 2015; 74:1667 – 75. 64 Isenberg DA et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebocontrolled study. Ann Rheum Dis 2016; 75:323 – 31. 65 Merrill JT et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebocontrolled study. Ann Rheum Dis 2016; 75:332 – 40. 66 Gatto M et al. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun 2016; 74:94-105. 67 Houssiau FA, Doria A. Targeting BAFF / BLyS in lupus: is the glass half-full or half-empty? Ann Rheum Dis 2016; 75:321 – 2. |
68 Wallace DJ et al. Efficacy and safety of epratuzumab in patients with moderate / severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies( ALLEVIATE) and follow-up. Rheumatology( Oxford) 2013; 52:1313 – 22. 69 Wallace DJ et al. Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014; 73:183 – 90. 70 Clowse MEB et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus: Results from two phase 3 randomized, placebocontrolled trials [ abstract ]. Arthritis Rheumatol 2015; 67. 71 Liang B et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006; 119:296 – 305. 72 Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993; 4:58 – 61. 73 Rovin BH et al. A Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab( CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 2016; 68:2174 – 83. 74 Illei GG et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542 – 52. 75 Ronnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17:394 – 9. 76 Khamashta M et al. Sifalimumab, an anti-interferonalpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebocontrolled study. Ann Rheum Dis 2016; 75:1909 – 16. 77 Kalunian KC et al. A Phase II study of the efficacy and safety of rontalizumab( rhuMAb interferonalpha) in patients with systemic lupus erythematosus( ROSE). Ann Rheum Dis 2016; 75:196 – 202. 78 Furie R et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus( SLE) [ abstract ]. Arthritis Rheumatol 2015; 67. 79 Merrill JT et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelvemonth, multicenter, exploratory, phase IIb, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2010; 62:3077-87. 80 van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 2013; 27:341 – 9. 81 Furie R et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014; 66:379 – 89. 82 Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64:3660 – 5. |
22 |
||||
HHE 2018 | hospitalhealthcare. com |